retatrutide phase 2 results A clinical trial demonstrates that #retatrutide, a triple agonist of the GIP, GLP-1, and glucagon receptors, in up to 82% reduction in liver fat #MASLD @ArunJSanyalVCU Effects of once-weekly subcutaneous retatrutide

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells that modulates glucose metabolism by controlling insulin excretion and glucagon secretion and inhibits gastric emptying leading to decreased food intake, thus limiting weight gain

If you are struggling with loss of vision or changes to your health due to taking GLP-1 drugs, you may have the right to seek legal action against the manufacturer

GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple AgonistsMechanism of Action and Emerging Therapeutic Landscape in #MASLD

Omada Health has signed on with Optum Rx to participate in its Weight Engage program, furthering the company's ability to scale its offerings to reach more people who need cardiometabolic care and | Omada Health has signed on with Optum Rx to participate in its Weight Engage program, furthering the company's ability to scale its offerings to reach more people who need cardiometabolic care and support.